Abstract
BACKGROUND: Birth cohort screening has been implemented in some countries to identify the potentially 'missed population' of undiagnosed chronic Hepatitis C Virus (HCV) in people who may not be found through targeted approaches.AIM: To determine uptake of HCV antibody testing using an oral swab screening method, overall yield, whether those testing positive had risk markers in their primary care record, and cost per case detected.
DESIGN AND SETTING: Pilot screening study set in general practices in the Southwest, South London and Yorkshire and Humber.
METHOD: Participants consenting were sent an oral swab kit in the post and saliva samples were tested for antibody to HCV.
RESULTS: 16,436/98,396 (16.7%) patients consented and were sent an oral swab kit. 12,216 (12.4%) returned a kit, with 31 participants (yield 0.03%) testing positive for HCV antibody. 45% of those positive had a risk marker for HCV on their primary care record. Two (yield 0.002%) were confirmed RNA positive and referred for treatment, both had HCV risk markers. Cost per case detected was £16,000 per HCV antibody and £247,997 per chronic HCV.
CONCLUSIONS: Wide-scale screening could be delivered and identified people infected with HCV, however most of these individuals could have been detected through lower-cost targeted screening. Yield and cost per case found were substantially worse than model estimates and targeted screening studies. Birth cohort screening should not be rolled out in primary care in England.
DESIGN AND SETTING: Pilot screening study set in general practices in the Southwest, South London and Yorkshire and Humber.
METHOD: Participants consenting were sent an oral swab kit in the post and saliva samples were tested for antibody to HCV.
RESULTS: 16,436/98,396 (16.7%) patients consented and were sent an oral swab kit. 12,216 (12.4%) returned a kit, with 31 participants (yield 0.03%) testing positive for HCV antibody. 45% of those positive had a risk marker for HCV on their primary care record. Two (yield 0.002%) were confirmed RNA positive and referred for treatment, both had HCV risk markers. Cost per case detected was £16,000 per HCV antibody and £247,997 per chronic HCV.
CONCLUSIONS: Wide-scale screening could be delivered and identified people infected with HCV, however most of these individuals could have been detected through lower-cost targeted screening. Yield and cost per case found were substantially worse than model estimates and targeted screening studies. Birth cohort screening should not be rolled out in primary care in England.
| Original language | English |
|---|---|
| Article number | BJGP.2024.0219. |
| Number of pages | 19 |
| Journal | The British journal of general practice : the journal of the Royal College of General Practitioners |
| Early online date | 5 Jul 2024 |
| DOIs | |
| Publication status | E-pub ahead of print - 5 Jul 2024 |
